Barclays PLC Has $185,000 Stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Barclays PLC lifted its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 196.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 277,682 shares of the company’s stock after acquiring an additional 183,861 shares during the quarter. Barclays PLC’s holdings in X4 Pharmaceuticals were worth $185,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $30,000. XTX Topco Ltd raised its holdings in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after purchasing an additional 46,397 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of X4 Pharmaceuticals in the third quarter worth $37,000. Finally, Point72 Asset Management L.P. boosted its holdings in X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares during the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on XFOR shares. Stifel Nicolaus dropped their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright dropped their price objective on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 5.1 %

Shares of XFOR opened at $0.70 on Wednesday. The firm has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.63. The company has a market cap of $119.72 million, a P/E ratio of -7.80 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a one year low of $0.26 and a one year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.